B. Metzler seel. Sohn & Co. Holding AG Purchases Shares of 411,290 Thermo Fisher Scientific Inc. (NYSE:TMO)

B. Metzler seel. Sohn & Co. Holding AG bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 411,290 shares of the medical research company's stock, valued at approximately $254,412,000. Thermo Fisher Scientific comprises 2.5% of B. Metzler seel. Sohn & Co. Holding AG's investment portfolio, making the stock its 10th biggest position. B. Metzler seel. Sohn & Co. Holding AG owned 0.11% of Thermo Fisher Scientific at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. BDF Gestion purchased a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $6,368,000. Nisa Investment Advisors LLC raised its position in Thermo Fisher Scientific by 6.2% in the third quarter. Nisa Investment Advisors LLC now owns 140,708 shares of the medical research company's stock worth $87,093,000 after acquiring an additional 8,180 shares in the last quarter. Simplify Asset Management Inc. boosted its position in shares of Thermo Fisher Scientific by 67.4% during the 3rd quarter. Simplify Asset Management Inc. now owns 13,770 shares of the medical research company's stock worth $8,518,000 after purchasing an additional 5,546 shares in the last quarter. Seven Eight Capital LP purchased a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at about $1,161,000. Finally, Simmons Bank lifted its stake in shares of Thermo Fisher Scientific by 60.2% in the third quarter. Simmons Bank now owns 8,224 shares of the medical research company's stock valued at $5,087,000 after purchasing an additional 3,090 shares during the period. Hedge funds and other institutional investors own 89.23% of the company's stock.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of research reports. Morgan Stanley lifted their price target on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an "overweight" rating in a research report on Friday, September 20th. Raymond James boosted their target price on Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an "outperform" rating in a research report on Thursday, July 25th. JPMorgan Chase & Co. lifted their price target on Thermo Fisher Scientific from $650.00 to $670.00 and gave the stock an "overweight" rating in a research note on Friday, September 20th. Robert W. Baird dropped their target price on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an "outperform" rating for the company in a report on Thursday, October 24th. Finally, Bernstein Bank increased their price target on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a "market perform" rating in a research report on Tuesday, October 22nd. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and an average price target of $649.33.

Thermo Fisher Scientific Stock Up 1.6 %

NYSE:TMO traded up $7.83 during mid-day trading on Tuesday, hitting $509.12. The company had a trading volume of 3,625,150 shares, compared to its average volume of 1,491,361. Thermo Fisher Scientific Inc. has a 1 year low of $465.90 and a 1 year high of $627.88. The business has a fifty day simple moving average of $584.05 and a 200-day simple moving average of $581.90. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $194.74 billion, a price-to-earnings ratio of 31.44, a PEG ratio of 3.39 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping analysts' consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The firm had revenue of $10.60 billion for the quarter, compared to analyst estimates of $10.63 billion. During the same quarter in the previous year, the business posted $5.69 EPS. The firm's revenue was up .2% compared to the same quarter last year. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.67 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th will be given a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.31%. The ex-dividend date is Friday, December 13th. Thermo Fisher Scientific's payout ratio is currently 9.78%.

Thermo Fisher Scientific declared that its Board of Directors has initiated a share buyback plan on Friday, November 15th that authorizes the company to repurchase $4.00 billion in shares. This repurchase authorization authorizes the medical research company to reacquire up to 2% of its stock through open market purchases. Stock repurchase plans are often a sign that the company's leadership believes its stock is undervalued.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the sale, the senior vice president now owns 12,736 shares of the company's stock, valued at $7,134,197.76. The trade was a 13.57 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $168,048.00. Following the completion of the transaction, the executive vice president now directly owns 16,663 shares of the company's stock, valued at approximately $9,333,946.08. The trade was a 1.77 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 37,150 shares of company stock valued at $20,651,865. Insiders own 0.34% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.